4 days ago
Dyne Therapeutics assumed with an Outperform at Raymond James
Raymond James analyst Martin Auster assumed coverage of Dyne Therapeutics (DYN) with an Outperform rating and $37 price target as part of a broader research note on selection Biotech names. Risk/reward skews favorably across the sector, though while companies with high PoS – probability of success – lead assets allow for higher conviction, highly attractive skews on less de-risked assets may deliver the most outsized returns, the analyst tells investors in a research note. For the stock, the firm notes that while it is trading at an enterprise value below $1B, Dyne's increasingly clinically-validated FORCE platform offers a compelling long-term risk-reward with proof of concept established on two assets in valuable, high unmet need markets, Raymond James added.
Confident Investing Starts Here:
